OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
TRDA
Entrada Therapeutics, Inc.
There isn't enough reported data to score TRDA yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
TRDA Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
TRDA's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
TRDA PE Valuation
TRDA has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
TRDA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect TRDA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over TRDA on earnings quality, reporting a profit while its opponent remains loss making.
TRDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.85 | -$1.36 |
| Q2 2026 | -$3.97 | -$2.19 |
| Q1 2026 | -$4.00 | -594% |
| Q4 2025 | -$3.47 | -282% |
| Q3 2025 | -$2.49 | -251% |
| Q2 2025 | -$1.78 | -159% |
| Q1 2025 | $0.81 | +17% |
| Q4 2024 | $1.91 | +$2.11 |
TRDA lost $3.85 per share over the past year, a bigger loss than the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over TRDA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over TRDA on profitability, with a higher operating margin.
TRDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $905K | -44% |
| Q2 2026 | $898K | -54% |
| Q1 2026 | $875K | -96% |
| Q4 2025 | $1.3M | -97% |
| Q3 2025 | $1.6M | -92% |
| Q2 2025 | $2M | -98% |
| Q1 2025 | $20.6M | -65% |
| Q4 2024 | $37.4M | -11% |
TRDA's revenue has slid since its 2024 peak: $905,000 last quarter, down 44% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4607% | -1691 points |
| Q2 2026 | -5007% | -2605 points |
| Q1 2026 | -4835% | -4729 points |
| Q4 2025 | -3249% | -3234 points |
| Q3 2025 | -2915% | -2805 points |
| Q2 2025 | -2403% | -2459 points |
| Q1 2025 | -106% | -142 points |
| Q4 2024 | -16% | -27 points |
TRDA's operating margin was −4607% last quarter, down 1691 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over TRDA on cash generation, producing positive trailing cash flow while its opponent burns cash.
TRDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$30.1M | -$2M |
| Q2 2026 | -$32.5M | -$2.7M |
| Q1 2026 | -$41.7M | -$2.1M |
| Q4 2025 | -$32M | +$244K |
| Q3 2025 | -$28.1M | -$3.2M |
| Q2 2025 | -$29.8M | -177% |
| Q1 2025 | -$39.7M | -$13.3M |
| Q4 2024 | -$32.2M | -$27.3M |
TRDA has burned cash in almost every quarter: −$136M over the past year, against −$130M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TRDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +152K shares |
| 1 year | +2.2% | +911K shares |
| 3 years | +22% | +7.6M shares |
| 5 years | +107% | +21.9M shares |
TRDA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
TRDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -8.7x | Net Cash |
| Q4 2024 | -2.0x | Net Cash |
| Q3 2024 | -1.3x | Net Cash |
| Q2 2024 | -1.9x | Net Cash |
| Q1 2024 | -2.5x | Net Cash |
TRDA has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
TRDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.2 | Neutral |
| Stochastic | 20.0 | Neutral |
TRDA's weekly RSI is 39 (neutral) and its Stochastic is 20 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TRDA PE vs Healthcare Sector
| Metric | TRDA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TRDA has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over TRDA on trend strength, trading above more of its moving averages.
TRDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.07 | 2% above |
| 20 week MA | $6.22 | 17% below |
| 50 week MA | $8.73 | 41% below |
| 100 week MA | $8.84 | 42% below |
| 200 week MA | $11.9 | 57% below |
TRDA has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 57% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over TRDA on returns for 2026, with the stronger performance.
TRDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.0 | $17.0 | -29% |
| 2022 | $17.0 | $15.0 | -12% |
| 2023 | $15.0 | $15.1 | +0.8% |
| 2024 | $15.1 | $17.4 | +15% |
| 2025 | $17.4 | $10.4 | -40% |
| 2026 YTD | $10.4 | $5.17 | -50% |
TRDA has finished lower in three of the last five years. It's down 50% so far in 2026.